Drug Company Will Buy Up to $700 Million in BNB After Coin Hits All-Time High
Windtree Therapeutics announced plans to purchase up to $700 million worth of BNB, the fifth-largest cryptocurrency, following its recent all-time high price of $808. The company, which trades on Nasdaq under ticker WINT, aims to bolster its balance sheet with these digital assets. Windtree is raising up to $520 million to fund the acquisition, building on a previous plan to invest $200 million. They will partner with Kraken for asset custody and have structured the funding through a $500 million equity line of credit from an institutional investor, alongside a $20 million stock purchase agreement with Build and Build Corp. The firm’s CEO emphasized that acquiring additional funds is crucial for their strategy. BNB, launched by Binance in 2017, has a current market cap of approximately $106.9 billion. The move follows a trend of publicly traded companies, like Windtree, seeking to enhance their stock prices and market presence through crypto investments, with other firms also making significant acquisitions.
Source 🔗